UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE
14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities
Exchange Act of 1934 (Amendment No. 1)
Filed
by the Registrant
x
Filed
by a Party other than the Registrant
¨
Check the appropriate box:
|
|
x
|
Preliminary Proxy Statement
|
|
|
¨
|
Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
|
¨
|
Definitive Proxy Statement
|
|
|
¨
|
Definitive Additional Materials
|
|
|
¨
|
Soliciting Material Pursuant to §240.14a-12
|
GENELINK, INC.
(Name of Registrant as Specified In Its
Charter)
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
Payment of Filing Fee (Check the appropriate
box):
|
|
¨
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
|
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on
which the filing fee is calculated and state how it was determined):
|
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
|
¨
|
Fee paid previously with preliminary materials.
|
|
|
¨
|
Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
|
|
|
(1)
|
Amount Previously Paid:
|
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
GENELINK, INC.
8250 Exchange Dr. Suite 120
Orlando, FL 32835
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD MAY 30, 2013
To the Shareholders of GeneLink, Inc.:
Notice is hereby given
that the Annual Meeting of Shareholders of GeneLink, Inc. (the “Company”), a Pennsylvania corporation, will be held
at 9:00 a.m. on Thursday, May 30, 2013 at the GeneLink Corporate Offices at 8250 Exchange Dr. Suite 120, Orlando, FL 32835, (the
“Annual Meeting”), for the following purposes:
|
|
1.
|
To approve and adopt an amendment to the Company’s Articles of Incorporation to increase
the Company’s capitalization from 350,000,000 shares of Common Stock, $0.01 par value, to 500,000,000 shares of Common Stock,
$0.01 par value;
|
|
|
2.
|
To cast a non-binding, advisory vote on executive compensation
|
|
|
3.
|
To cast a non-binding, advisory vote on the frequency of which future advisory votes on executive compensation should be asked.
|
|
|
4.
|
To transact such other business as may properly be brought before the Annual Meeting or any adjournment(s)
thereof.
|
Only shareholders of
record at the close of business on April 1, 2013, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment(s)
or postponement(s) thereof.
The Annual Meeting
may be adjourned from time to time without notice other than by announcement at the Annual Meeting. We are providing a copy of
our Annual Report on Form 10-K for the fiscal year ended December 31, 2012 with this proxy statement.
Your vote is important.
Whether or not you plan to attend the meeting in person, we urge you to complete, date and sign the enclosed proxy card and return
it promptly in the enclosed return envelope or vote according to the internet instructions provided. A prompt submission will ensure
a quorum and save the Company the expense of further solicitation. Each proxy granted may be revoked by the shareholder appointing
such proxy at any time before it is voted. If you receive more than one proxy card because your shares are registered in different
names or addresses, each such proxy card should be signed and returned to assure that all of your shares will be voted
.
|
|
By Order of the Board of Directors,
|
|
|
|
|
|
Bernard L. Kasten, Jr., M.D.
|
|
|
Chairman of the Board
|
April XX, 2013
GENELINK, INC.
8250 Exchange Dr. Suite 120
Orlando, FL 32809
PROXY STATEMENT
Annual Meeting of Shareholders
May 30, 2013
This Proxy Statement
is furnished to shareholders of GeneLink, Inc. (the “Company”), a Pennsylvania corporation, in connection with the
solicitation of proxies on behalf of the management of the Company for use at the Annual Meeting of Shareholders to be held at
The GeneLink Corporate Office at 8250 Exchange Dr. Suite 120, Orlando, FL 32809 on Thursday, May 30, 2013, at 9:00 a.m. and at
any and all postponements or adjournment thereof (the “Annual Meeting”), for the purpose of considering and acting
upon the matters set forth in the attached Notice of Annual Meeting and more fully discussed below.
This Proxy Statement and the accompanying
form of proxy were first mailed to shareholders of the Company entitled to notice of the Annual Meeting on or about April XX, 2013.
Quorum and Voting
The presence, in person
or by proxy, of the holders of a majority of the shares of Common Stock issued and outstanding, is necessary to constitute a quorum
at the Annual Meeting. Shareholders are entitled to one vote per share of Common Stock held on any matter which may properly come
before the Annual Meeting.
Any shareholder executing
and delivering the accompanying proxy has the power to revoke the same by giving notice to the Secretary of the Company. The presence
at the Annual Meeting of a shareholder will not revoke his or her proxy. Proxies in the accompanying form which are properly executed,
duly returned to the Company, and not revoked will be voted in accordance with the instructions therein.
Shareholders may vote
via the Internet by following the instructions on their proxy card. When voting via the Internet, Shareholders must have available
the control number included on their proxy cards. Abstentions and broker non-votes will be counted for purposes of determining
a quorum, but will not be counted as votes cast. A broker non-vote occurs when a bank, broker, or other nominee holding shares
for a beneficial owner has not received voting instruction from the beneficial owner on a particular matter and the bank, broker,
or nominee cannot vote the shares on such matter because the matter is not considered routine.
Under Pennsylvania
law, the approval of Proposal I, the amendment to Articles of Incorporation to increase the authorized shares of Common Stock,
Proposal II, the non-binding advisory vote on executive compensation, and Proposal III, the non-binding advisory vote on the frequency
of future non-binding advisory vote on executive compensation require the affirmative vote of at least a majority of the votes
cast by shareholders present, in person or by proxy, at the meeting. Abstention and broker non-votes will, therefore, have no effect
in determining the outcome of any of these matters.
Shareholders will not
have dissenters’ rights under the Pennsylvania Business Corporation Law in connection with the approval and adoption of the
proposed amendment to the Company’s Articles of Incorporation.
IF NO INSTRUCTION
IS GIVEN WITH RESPECT TO ANY PROPOSAL TO BE ACTED UPON, THE PROXY WILL BE VOTED ON FOR APPROVAL OF THE AMENDMENT TO THE COMPANY’S
ARTICLES OF INCORPORATION, FOR APPROVAL, ON AN ADVISORY BASIS, OF THE EXECUTIVE COMPENSATION, AND THE ADVISORY VOTE ON EXECUTIVE
COMPENSATION BE HELD EVERY THREE YEARS
. No matter is expected to be considered at the Meeting other than the proposals set
forth in the accompanying Notice of Annual Meeting, but if any other matters are properly brought before the Meeting for action,
it is intended that the persons named in the proxy and acting thereunder will vote their discretion on such matters.
Record Date and Shares Outstanding
The close of business
on April 1, 2013 has been fixed as the record date for the determination of shareholders entitled to receive notice of, and to
vote at, the Annual Meeting. The stock transfer books will not be closed. As of April 1, 2013, there were issued and outstanding
253,352,022 shares of the Company’s Common Stock.
PRINCIPAL
SHAREHOLDERS
Security Ownership of Management and Certain
Beneficial Owners
The following table
sets forth certain information as of April 1, 2013 regarding the ownership of Common Stock (i) by each person known by the Company
to be the beneficial owner of more than five percent of the outstanding Common Stock, (ii) by each current officer and director
of the Company, (iii) by each nominee for director, and (iv) by all current officers and directors of the Company as a group.
The beneficial owners
and amount of securities beneficially owned have been determined in accordance with Rule 13d-3 under the Exchange Act and, in accordance
therewith, includes all shares of the Company’s Common Stock that may be acquired by such beneficial owners within 60 days
of April 1, 2013 upon the exercise or conversion of any options, warrants or other convertible securities. This table has been
prepared based on 253,352,022 shares of Common Stock outstanding on April 1, 2013. Unless otherwise indicated, each person or entity
named below has sole voting and investment power with respect to all Common Stock beneficially owned by that person or entity,
subject to the matters set forth in the footnotes to the table below. Unless otherwise stated, the beneficial owners exercise sole
voting and/or investment power over their shares.
|
Name
|
|
Number of Shares
Beneficially Owned
|
|
|
Approximate Percentage
Of Stock Outstanding
|
|
Jon A. Marshall
3330 Willowfork Place
Katy, TX 77494
|
|
|
41,666,667
|
|
|
|
16.3
|
%
|
Kenneth R. Levine
2 Oaklawn Road
Short Hills, NJ 07078
|
|
|
26,130,706
|
(1)
|
|
|
9.7
|
%
|
Robert Trussell
167 W. Main Street
Suite 1500
Lexington, KY 40507
|
|
|
16,166,667
|
(2)
|
|
|
6.3
|
%
|
Gene Elite, LLC
1481 North Ocean Boulevard
Pompano Beach, FL 33062
|
|
|
14,000,000
|
(3)
|
|
|
5.3
|
%
|
|
Chesed Congregation of America
One State Street Plaza, 29
th
Floor
New York, NY 10004
|
|
|
13,958,334
|
(4)
|
|
|
5.2
|
%
|
|
Bernard L. Kasten, Jr. M.D.
4380 27
th
Court S.W., Apt. 104
Naples, FL 34116
|
|
|
13,084,894
|
(5)
|
|
|
5.0
|
%
|
Robert P. Ricciardi, Ph.D.
831 Newhall Road
Kennett Square, PA 19348
|
|
|
6,635,000
|
(6)
|
|
|
2.6
|
%
|
James Monton
11489 Grandstone Lane
Cincinnati, Ohio 45249
|
|
|
1,337,500
|
(7)
|
|
|
*
|
|
Douglas M. Boyle, DBA
111 Weatherly Street
Dalton, PA 18414
|
|
|
925,000
|
(8)
|
|
|
*
|
|
Michael Smith
3732 Winding Lake Cir
Orlando, FL 32835
|
|
|
125,000
|
(9)
|
|
|
*
|
|
|
Directors, Officers and Management as a Group
|
|
|
22,107,394
|
(5)(6)(7)(8)(9)
|
|
|
8.4
|
%
|
|
|
(1)
|
Includes shares and currently exercisable options to acquire 643,750 shares of Common stock and 350,000 shares of Common Stock
held by a retirement plan for Mr. Levine. Also includes shares and currently exercisable warrants to acquire 13,270,737 shares
of Common Stock held by First Equity Capital Securities, Inc. of which Mr. Levine is president and owner.
|
|
|
(2)
|
Includes shares and currently exercisable warrants to acquire 875,000 shares of Common Stock.
|
|
|
(3)
|
Includes shares and currently exercisable warrants to acquire 8,000,000 shares of Common Stock.
|
|
|
(4)
|
Includes 13,333,334 shares of Common Stock issuable upon the conversion of convertible notes as of February 28, 2013. Chesed
holds $1,000,000 principal balance of convertible notes, which have accrued $333,334 of interest through February 28, 2013 and
convert at an exercise price of $.10 per share.
|
|
|
(5)
|
Includes shares and currently exercisable options to acquire 3,916,625 shares of Common Stock.
|
|
|
(6)
|
Includes shares and currently exercisable options and warrants to acquire 2,125,000 shares of Common Stock.
|
|
|
(7)
|
Includes shares and currently exercisable options and warrants to acquire 512,500 shares of Common Stock.
|
|
|
(8)
|
Includes currently exercisable options and warrants to acquire 550,000 shares of Common Stock.
|
|
|
(9)
|
Includes currently exercisable options to acquire 125,000 shares of Common Stock
|
*less than 1%
Certain Relationships and Related Transactions
During the year ended
December 31, 2012, the Company sold 52,500,000 shares of restricted Common Stock of the Company at an exercise price of $0.03 per
share pursuant to a Confidential Private Offering Memorandum, and received an aggregate gross amount of $1,504,000.
In connection with
the above offering, the Company incurred a total of $71,000 in placement fees and expenses and issued warrants to acquire 5,041,667
shares of Common Stock at an exercise price of $0.03 per share to First Equity Capital Securities, Inc., as placement agent, in
connection with the sale of some of these units. Kenneth R. Levine, a holder of more than five percent of the equity securities
of the Company and a member of the Company’s Scientific Advisory Board, is an officer and owner of First Equity Capital Securities,
Inc.
During the year ended
December 31, 2011, the Company sold 48,270,000 shares of restricted Common Stock of the Company at an exercise price of $0.05 per
share pursuant to a Confidential Private Offering Memorandum, and received an aggregate gross amount of $2,413,500.
In connection with
the above offering, the Company incurred a total of $125,180 in placement fees and expenses and issued warrants to acquire 3,104,500
shares of Common Stock at an exercise price of $0.05 per share to First Equity Capital Securities, Inc., as placement agent, in
connection with the sale of some of these units. Kenneth R. Levine, a holder of more than five percent of the equity securities
of the Company and a member of the Company’s Scientific Advisory Board, is an officer and owner of First Equity Capital Securities,
Inc.
Kenneth R. Levine, a holder of more than
five percent of the equity securities of the Company, is the President and owner of First Equity. First Equity has been engaged
by the Company to perform investment banking services since 2003, including capital formation, for which First Equity has, from
time to time, acted as a Placement Agent for compensation. Although First Equity receives a stipend of $5,000 per month for
such services, payment is reviewed monthly by the Company’s Chairman, Dr. Bernard Kasten, who will decide whether any payment
is due and whether such payment should be released or accrued. At the invitation of Dr. Kasten, Mr. Levine may attend Board of
Directors and Audit Committee meetings on behalf of First Equity as a non-voting observer. Mr. Levine is also a member of the Company’s
Scientific Advisory Board.
.
On March 2, 2012, First Equity converted its accrued stipend for 2011 and the first three months of 2012 amounting to $74,361
in exchange for 1,497,226 restricted shares of GeneLink common stock. Such shares were issued into the name Kenneth R. Levine,
principal and owner of First Equity. On March 15, 2012, GeneLink paid to First Equity a consulting fee in the amount of $80,000
in consideration for First Equity's work in relation to the transactions resulting in the Stock Purchase Agreement, the LDA and
the closing thereof. GeneLink has agreed that certain legal fees incurred by First Equity are related to private placement services
provided First Equity to GeneLink. During the year ended December 31, 2012 GeneLink reimbursed First Equity $105,647 for such legal
fees
EXECUTIVE COMPENSATION
|
SUMMARY
COMPENSATION TABLE
|
|
Name and
principal
position
|
|
|
Year
|
|
|
Salary
($)
|
|
|
Bonus
($)
|
|
|
Stock
Awards
($)
|
|
|
Option
Awards
($)
|
|
|
Non-Equity
Incentive Plan
Compensation
($)
|
|
|
Nonqualified
Deferred
Compensation
Earnings
($)
|
|
|
All
Other
Compensation
($)
|
|
|
Total
($)
|
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
(i)
|
|
|
(j)
|
|
|
Bernard L. Kasten Jr., M.D.
|
|
|
2012
|
|
|
|
15,954
|
|
|
|
-
|
|
|
|
-
|
|
|
|
71,938
|
|
|
|
-
|
|
|
|
-
|
|
|
|
7,768
|
|
|
|
95,660
|
|
|
Chief Executive Officer (1)
|
|
|
2011
|
|
|
|
15,152
|
|
|
|
-
|
|
|
|
-
|
|
|
|
201,563
|
|
|
|
-
|
|
|
|
-
|
|
|
|
8,229
|
|
|
|
224,944
|
|
|
John A Webb, CFO/Vice
|
|
|
2012
|
|
|
|
99,130
|
|
|
|
-
|
|
|
|
-
|
|
|
|
27,750
|
|
|
|
-
|
|
|
|
-
|
|
|
|
5,989
|
|
|
|
132,869
|
|
|
President of Operations (2)
|
|
|
2011
|
|
|
|
110,000
|
|
|
|
19,250
|
|
|
|
-
|
|
|
|
69,813
|
|
|
|
-
|
|
|
|
-
|
|
|
|
11,543
|
|
|
|
210,606
|
|
|
Susan Hunt, Interim CFO (3)
|
|
|
2012
|
|
|
|
71,193
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,287
|
|
|
|
77,480
|
|
1
Dr. Kasten was appointed
Chief Executive Officer on December 30, 2010. Dr. Kasten’s compensation as CEO is presently set at minimum wage, and includes
health care benefits. No employment contract exists for Dr. Kasten. Because of the late appointment in 2010, all compensation
for that year relates to service as Chairman of the Board of Directors for that year.
2
Mr. Webb was appointed Chief
Financial Officer on June 1, 2011. His employment provides for a base salary of $110,000 plus healthcare and vacation benefits.
The agreement also allows for certain bonus, separation and termination provisions. Mr. Webb received a bonus of $19,250 in 2011.
Mr. Webb’s employment ended on July 13, 2012. Separation compensation of $27,500 is included in base pay amounts.
3
Ms. Hunt was appointed Interim
Chief Financial Officer on July 13, 2012. Her base salary is $75,000 plus healthcare and vacation benefits.
Agreements with Executive Officers
The Company has entered
into a consulting agreement with Dr. Ricciardi (shareholder and officer) dated February 24, 1998. The initial term of the agreement
was five (5) years. Pursuant to an agreement dated September 27, 2007, Dr. Ricciardi agreed to reduce the accrued compensation
payable to him to $90,000 as of September 30, 2007, payable when the Board of Directors of the Company determines that the Company’s
financial position can accommodate such payments, and to reduce the compensation payable to him for future services to be rendered
pursuant to the consulting arrangement to $30,000 per year, payable in monthly installments of $2,500 each commencing, October
2007 and payable on the last day of each month. On January 18, 2011, Dr. Ricciardi chose to apply and convert to common stock his
accrued compensation of $90,000 to 1,800,000 shares in the Confidential Private Placement.
John A. Webb, former
CFO and Vice President of Operations, entered into an employment agreement with the Company effective February 16, 2010. His
position at the time was Controller for the Company. Pursuant to this employment agreement, Mr. Webb received an annual base
salary of $110,000, is entitled to receive annual bonuses based on personal and Company performance and is entitled to receive
severance payments if he is terminated without cause. Mr. Webb received bonuses in 2011 of $19,250, and no bonus was
received for 2012. Mr. Webb’s employment terminated July 13, 2012 and he received severance payments of $27,500 through November
16, 2012 and continued health insurance coverage through September 30, 2012.
OUTSTANDING
EQUITY AWARDS AT FISCAL YEAR END
|
OPTION AWARDS
|
|
Name
(a)
|
|
Number of Securities
Underlying Unexercised
Options (#)
Exercisable
(b)
|
|
|
Number of Securities
Underlying Unexercised
Options (#)
Unexercisable
(c)
|
|
|
Equity Incentive Plan
Awards: Number of
Securities Underlying
Unexercised Unearned
Options
(#)
(d)
|
|
|
Option
Exercise
Price
($)
(e)
|
|
|
Option Expiration
Date
(f)
|
|
|
Bernard L. Kasten, Jr., M.D.
|
|
|
1,625,000
|
|
|
|
|
|
|
|
|
|
|
$
|
0.08
|
|
|
June 1, 2017
|
|
|
Bernard L. Kasten, Jr., M.D
|
|
|
100,000
|
|
|
|
|
|
|
|
|
|
|
$
|
0.12
|
|
|
May 20, 2018
|
|
|
Bernard L. Kasten, Jr., M.D.
|
|
|
325,000
|
|
|
|
495,833
|
|
|
|
|
|
|
$
|
0.50
|
|
|
July 28, 2018
|
|
|
Bernard L. Kasten, Jr., M.D
|
|
|
1,012,500
|
|
|
|
337,500
|
|
|
|
|
|
|
$
|
0.08
|
|
|
July 7, 2020
|
|
|
Bernard L. Kasten, Jr., M.D
|
|
|
218,750
|
|
|
|
218,750
|
|
|
|
|
|
|
$
|
0.10
|
|
|
January 25, 2021
|
|
|
Bernard L. Kasten, Jr., M.D
|
|
|
300,000
|
|
|
|
800,000
|
|
|
|
|
|
|
$
|
0.08
|
|
|
May 20, 2021
|
|
|
Bernard L. Kasten, Jr., M.D
|
|
|
25,000
|
|
|
|
75,000
|
|
|
|
|
|
|
$
|
0.03
|
|
|
September 1, 2022
|
|
|
John A. Webb
|
|
|
250,000
|
|
|
|
|
|
|
|
|
|
|
$
|
0.50
|
|
|
July 28, 2018
|
|
|
John A. Webb
|
|
|
250,000
|
|
|
|
|
|
|
|
|
|
|
$
|
0.13
|
|
|
February 16, 2020
|
|
|
John A. Webb
|
|
|
262,500
|
|
|
|
|
|
|
|
|
|
|
$
|
0.10
|
|
|
January 25, 2021
|
|
|
John A. Webb
|
|
|
100,000
|
|
|
|
|
|
|
|
|
|
|
$
|
0.08
|
|
|
May 20, 2021
|
|
|
John A. Webb
|
|
|
137,500
|
|
|
|
|
|
|
|
|
|
|
$
|
0.06
|
|
|
January 1, 2022
|
|
|
Susan Hunt
|
|
|
37,500
|
|
|
|
112,500
|
|
|
|
|
|
|
$
|
0.02
|
|
|
July 1, 2022
|
|
director
compensation
Directors do not receive any cash compensation
for their service as directors of the Company or for attending any meetings.
|
DIRECTOR COMPENSATION
|
|
Name
(a)
|
|
Fees
Earned
($)
(b)
|
|
|
Stock
Awards
($)
(c)
|
|
|
Options
Awards
($)
(d)
|
|
|
Non-Equity
Incentive Plan
Compensation
($)
(e)
|
|
|
Change in
Pension Value
and Nonqualified
Deferred
Compensation
($)
(f)
|
|
|
All Other
Compensation
($)
(g)
|
|
|
Total
($)
(h)
|
|
Douglas M. Boyle,
DBA (1)
|
|
|
|
|
|
|
|
|
|
|
15,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000
|
|
|
James A. Monton (2)
|
|
|
|
|
|
|
|
|
|
|
3,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000
|
|
|
Robert P. Ricciardi, Ph.D. (3)
|
|
|
30,000
|
|
|
|
|
|
|
|
3,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33,000
|
|
|
Bernard L. Kasten, Jr. M.D.
|
|
|
|
|
|
|
|
|
|
|
3,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000
|
|
(1)
On September 1, 2012 Dr. Boyle received options
to acquire 500,000 shares of Common Stock at an exercise price of $0.03 per share, of which one fourth vested immediately and one
fourth vest additionally on each of the next three anniversary dates thereafter.
(2)
On September 1, 2012 Mr. Monton received options
to acquire 100,000 shares of Common Stock at an exercise price of $0.03 per share, of which one fourth vested immediately and one
fourth vest additionally on each of the next three anniversary dates thereafter.
(3)
On September 1, 2012 Dr. Ricciardi received options
to acquire 100,000 shares of Common Stock at an exercise price of $0.03 per share, of which one fourth vested immediately and one
fourth vest additionally on each of the next three anniversary dates thereafter. Dr. Ricciardi also received a stipend of $30,000
for consulting services to the Company.
(4)
On September 1, 2012 Dr. Kasten received
options to acquire 100,000 shares of Common Stock at an exercise price of $0.03 per share, of which one fourth vested immediately
and one fourth vest additionally on each of the next three anniversary dates thereafter. Dr. Kasten also serves as CEO of GeneLink
and additional compensation information is included in the executive compensation table above.
Compensation Discussion and Analysis
Our compensation program
for senior executives is administered by the Compensation Committee of our Board of Directors. The Compensation Committee is responsible
for considering and making recommendations to the Board of Directors regarding executive compensation and is responsible for administering
our stock option and executive incentive compensation plans. The Compensation Committee is committed to ensure that its compensation
plan is consistent with our company goals and objectives and the long term interests of its shareholders.
Overview of Compensation Philosophy and Objectives
Our compensation programs
are designed to deliver a compensation package which is competitive in attracting and retaining key executive talent in our industry.
Different programs are geared to short and longer term performance with the goal of increasing shareholder value over the long
term. The Compensation Committee believes that our executive compensation should encompass the following:
|
|
·
|
help attract and retain the most qualified
individuals by being competitive with compensation packages paid to persons having similar responsibilities and duties in comparable
businesses;
|
|
|
·
|
motivate and reward individuals who help
us achieve our short term and long term objectives and thereby contribute significantly to the success of our company;
|
|
|
·
|
relate to the value created for shareholders
by being directly tied to our financial performance and condition and the particular executive officer’s contribution; and
|
|
|
·
|
reflect the qualifications, skills, experience,
and responsibilities of the particular executive officer.
|
The Compensation Committee has
approved a compensation structure for the named executive officers, determined on an individual basis, which incorporates four
key components: base salary, bonuses commencing in 2012 based upon the annual performance of the Company, stock options and other
benefits.
In connection with
its compensation determinations, the Compensation Committee seeks the views of the Chief Executive Officer with respect to appropriate
compensation levels of the other officers.
Executive Compensation Components
For the year ended
December 31, 2012, the principal components of compensation for the named executive officers were annual base salary, stock
options and other benefits.
Annual Base Salary
In general, base salary
for each employee, including the named executive officers, is established based on the individual’s job responsibilities,
performance and experience; our size relative to competitors; the competitive environment; a general view as to available resources
of the Company and the compensation agreed to in employment agreements with the named executive officers.
Stock Options and Stock Awards
We provide a long term
incentive opportunity for each of the named executive officers through awards of stock options. Our stock option program is a long
term plan designed to create a link between executive compensation and our financial performance, provide an opportunity for increased
equity ownership by executives, and maintain competitive levels of total compensation.
All stock options have
been granted at an exercise price equal to or above the closing market price of our common stock on the date of grant. Stock options
generally vest in four equal annual installments; however, options will immediately vest in full upon a change on control of the
Company. Stock options expire ten years from date of grant.
Other Benefits
|
|
·
|
Medical Benefits
. Our employees have a choice of coverage options
under our company-sponsored group health insurance plan. Each option covers the same services and supplies but differs in the quality
of provider network.
|
|
|
·
|
Life Insurance
. We maintain a basic
group life insurance plan that provides for basic life and accidental death and dismemberment coverage. We pay the premiums under
this plan.
|
|
|
·
|
Vacation and paid time off
. All employees are eligible for
paid vacation based on years of service as well as sick and other personal time.
|
|
|
·
|
Other Perquisites
. Nutritional
and skin care products are made available for certain executives and immediate family.
|
|
|
·
|
Retirement Benefits.
We have begun
to establish a 401(k) plan for our employees and it is anticipated to be effective May 1, 2013. Named executive officers would
be eligible to participate in these plans on the same terms as other eligible employees, subject to any legal limits on the amount
that may be contributed by executives under the plans.
|
Deductibility of Compensation Expenses
Pursuant to Section 162(m)
under the Internal Revenue Code, certain compensation paid to executive officers in excess of $1 million is not tax deductible,
except to the extent such excess constitutes performance-based compensation. The Compensation Committee has and will continue to
carefully consider the impact of Section 162(m) when establishing incentive compensation plans and could, in certain circumstances,
approve and authorize compensation that is not fully tax deductible.
Accounting and Tax Considerations
We consider the accounting
implications of all aspects of our executive compensation program. Our executive compensation program is designed to achieve the
most favorable accounting (and tax) treatment possible as long as doing so does not conflict with the intended plan design or program
objectives.
REPORT OF COMPENSATION COMMITTEE
The Compensation Committee of our Board
of Directors currently consists of Mr. Monton (Chair) and Mr. Boyle. The Compensation Committee is responsible for considering
and making recommendations to the Board of Directors regarding executive compensation and is responsible for administering our
stock option and executive incentive compensation plans.
The Compensation Committee has reviewed
and discussed with management the Compensation Discussion and Analysis included in this report. Based on the review and discussion
with management, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis
be included in the Company’s Annual Report on Form 10-K.
|
|
|
|
|
|
|
COMPENSATION COMMITTEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James Monton (Chair)
Douglas M. Boyle
|
OFFICERS
AND DIRECTORS
Information with respect to each of the
executive officers and current directors of the Company is set forth below
|
Name
|
|
Age
|
|
Position
|
|
Bernard L. Kasten, Jr. M.D.
|
|
66
|
|
Executive Chairman of the Board, Director, Chief Executive Officer, Interim Chief Financial Officer
|
|
Douglas M. Boyle
|
|
46
|
|
Director
|
|
James A. Monton
|
|
64
|
|
Director
|
|
Robert P. Ricciardi, Ph.D.
|
|
64
|
|
Chief Science Officer, Secretary, Director
|
|
Michael Smith
|
|
46
|
|
Senior Vice President of Operations
|
The nominees for director and the descriptions
for each appear under the caption “Nominees for Director” beginning on page 13. The names and descriptions of any director
not continuing beyond this current term are below:
Audit Committee
Mr. Boyle (Chair) and
Mr. Monton, who both are independent members of the Board of Directors, served on the Audit Committee for the fiscal year ended
December 31, 2012. The Board of Directors has determined that Mr. Boyle, a director of the Company, is the audit committee
financial expert as defined in section 3(a)(58) of the Exchange Act and the related rules of the SEC, based upon his professional
and educational background as set forth above in this Item 10.
Consistent with SEC
policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation and overseeing
the work of the independent auditor. In recognition of this responsibility, the Audit Committee has established a policy to pre-approve
all audit and permissible non-audit services provided by the independent registered public accounting firm. Prior to engagement
of the independent auditor for the next year’s audit, management will submit a detailed description of the audit and permissible
non-audit services expected to be rendered during that year for each of four categories of services described above to the Audit
Committee for approval. In addition, management will also provide to the Audit Committee for its approval a fee proposal for the
services proposed to be rendered by the independent auditor. Prior to the engagement of the independent auditor, the Audit Committee
will approve both the description of audit and permissible non-audit services proposed to be rendered by the independent auditor
and the budget for all such services. The fees are budgeted and the Audit Committee requires the independent registered public
accounting firm and management to report actual fees versus the budget periodically throughout the year by category of service.
During the year, circumstances
may arise when it may become necessary to engage the independent registered public accounting firm for additional services not
contemplated in the original pre-approval. In those instances, the Audit Committee requires separate pre-approval before engaging
the independent registered public accounting firm. To ensure prompt handling of unexpected matters, the Audit Committee may delegate
pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational
purposes only, any pre-approval decisions to the Audit Committee at its next scheduled meeting. The four categories of services
provided by the independent registered public accounting firm are as defined in the footnotes to the fee table set forth above.
Nominating Committee
The Board of Directors
has not created a standing Nominating Committee. The directors are or have been actively involved in the Company’s business
and all are able to contribute valuable insights into the identification of suitable candidates for nomination to the Board. As
a result, the Company believes that it is in its best interest that the entire Board oversees the composition of the Board of Directors
and therefore, the Company has not created a standing nominating committee of the Board. Recommendations to the Board of Directors
are approved by a majority of directors. The full Board of Directors is responsible for identifying and evaluating individuals
qualified to become Board members and to recommend such individuals for nomination. All candidates must possess an unquestionable
commitment to high ethical standards and have a demonstrated reputation for integrity. Other facts considered include an individual’s
business experience, education, civic and community activities, knowledge and experience with respect to the issues impacting the
biogenetic industry and public companies, as well as the ability of the individual to devote the necessary time to service as a
director.
The Board of Directors
does not have a formal policy with regard to the consideration of any director candidates recommended by security holders. The
Board of Directors will consider candidates recommended by shareholders. All nominees will be evaluated in the same manner, regardless
of whether they were recommended by the Board of Directors, or recommended by a shareholder. This will ensure that appropriate
director selection continues.
Section 16(a) Beneficial
Ownership Reporting Compliance.
Based solely on the
Company’s review of certain reports filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities
Exchange Act of 1934, as amended (the “1934 Act”), and written representations of the Company’s officers and
directors, the Company believes that all reports required to be filed pursuant to the 1934 Act with respect to transactions in
the Company’s Common Stock through December 31, 2012 were filed on a timely basis.
Code of Ethics.
The Company has adopted
a code of conduct that applies to all employees, including the Company’s principal executive officer, principal financial
officer, principal accounting officer or controller and persons performing similar functions. A copy of the Company’s code
of conduct will be provided to anyone without charge upon request therefor.
Meeting of Directors
The Board of Directors met 10 times in 2012.
Each director attended at least 75% of the meetings.
Communications with the Board of Directors
You may contact the
Board of Directors as a group by writing to them c/o GeneLink, Inc., 8250 Exchange Dr. Suite 120, Orlando, FL 32809, Attention:
Chairman. Any communications received will be forwarded to all Board members.
REPORT
FROM THE AUDIT COMMITTEE
The Audit Committee
is responsible for considering management’s recommendation of independent certified public accountants for each fiscal year,
recommending the appointment or discharge of independent accountants to the board of directors and confirming the independence
of the accountants. It is also responsible for reviewing and approving the scope of the planned audit, the results of the audit
and the accountants’ compensation for performing such audit, reviewing the Company’s audited financial statements,
and reviewing and approving the Company’s internal accounting controls and discussing such controls with the independent
accountants.
In connection with
the audit of the Company’s financial statements for the year ended December 31, 2012, the Audit Committee met with representatives
from Hancock Askew & Co., LLP, the Company’s independent auditors. The Audit Committee reviewed and discussed with the
Company’s financial management and financial structure, as well as the matters relating to the audit required to be discussed
by Statements on Auditing Standards 61 and 90.
Based upon the review
and discussions described above, the Audit Committee recommended to the Board of Directors that the Company’s financial statements
audited by Hancock Askew & Co., LLP be included in the Company’s Annual Report on Form 10-K for year ended December 31,
2012 and December 31, 2011.
|
|
Douglas M. Boyle (Chair)
|
|
|
James Monton
|
INDEPENDENT PUBLIC ACCOUNTANTS
Hancock Askey & Co., LLP was the Company’s
independent public accountant for the years ended December 31, 2012 and December 31, 2011. Hancock Askew & Co., LLP audited
the 2012 and the 2011 statements included in the 2012 10-K statement.
Fees for Independent Auditors for Fiscal Years 2012 and
2011
Set forth below are the fees billed for
services rendered by Hancock Askew & Co., LLP in 2012 and 2011.
|
|
|
2012
|
|
|
2011
|
|
|
Audit Fees
|
|
$
|
48,500
|
|
|
$
|
25,000
|
|
|
Audit-Related Fees
|
|
|
0
|
|
|
|
0
|
|
|
Tax Fees
|
|
|
0
|
|
|
|
0
|
|
|
All Other Fees
|
|
|
0
|
|
|
|
0
|
|
|
Total Fees
|
|
$
|
48,500
|
|
|
$
|
25,000
|
|
Audit fees consist
of fees billed for professional services rendered by the Company’s independent accountant for the audit of the Company’s
annual financial statements, review of financial statements included in quarterly reports on Form 10-Q and services that are normally
provided by the independent accountant in connection with statutory and regulatory filings or engagements.
Audit Committee Pre-Approval
Procedures.
The Audit Committee approves the engagement of the independent auditors, and meets with the independent auditors
to approve the annual scope of accounting services to be performed and the related fee estimates. It also meets with the independent
auditors, on a quarterly basis, following completion of their quarterly reviews and annual audit and prior to our earnings announcements,
if any, to review the results of their work. During the course of the year, the chairman has the authority to pre-approve requests
for services that were not approved in the annual pre-approval process. The chairman reports any interim pre-approvals at the following
quarterly meeting. At each of the meetings, management and the independent auditors update the Audit Committee with material changes
to any service engagement and related fee estimates as compared to amounts previously approved. During 2012, all audit and non-audit
services performed by our independent accountants were pre-approved by the Audit Committee in accordance with the foregoing procedures.
PROPOSAL
I
PROPOSED
AMENDMENT TO THE
ARTICLES
OF INCORPORATION
On March 22, 2013,
the Board of Directors adopted a resolution proposing that Article 4 of the Company’s Articles of Incorporation be amended
to increase the authorized shares of the Capital Stock of the Corporation from 350,000,000 shares of Common Stock, $0.01 par value
to 500,000,000 shares of Common Stock, $0.01 par value (the “Amendment”). The Board directed that the proposed Amendment
be submitted to a vote of the shareholders at the Annual Meeting.
As of April 1, 2013,
253,352,022 shares of Common Stock were issued and outstanding and 64,320,542 shares were reserved for issuance upon exercise of
options or warrants or the conversion of convertible debentures. The Board of Directors believes that the flexibility provided
by the Amendment to permit the Company to issue or reserve additional Common Stock, in the discretion of the Board and without
the delay or expense of calling and convening a special meeting of shareholders, is in the best interests of the Company and its
shareholders. Shares of Common Stock may be used for general purposes, including stock splits and stock dividends, acquisitions,
possible financing activities, and other employee, executive and director benefit plans, including the 2011 Stock Option Plan.
Upon approval of the proposed Amendment by the Shareholders, the Company will have authority to issue 500,000,000 shares of Common
Stock. The Company has no present plans, arrangements, commitments or understanding with respect to the issuance of any of the
additional shares of Common Stock that would be authorized by adoption of the Amendment, other than the reservation of the remaining
3,790,000 shares in connection with the 2011 Stock Option Plan.
If the Amendment is
not approved, the Company may not be able to issue a sufficient amount of additional shares of Common Stock or securities convertible
into shares of Common Stock to raise future funds needed to operate the Company’s business operations and implement its business
and marketing initiatives. In such event, the only remaining option to finance the Company’s operations would be to borrow
funds to the extent that such financing would be available on terms acceptable to the Company. If that were unsuccessful, the Company
would be forced to cease its operations.
If the Amendment were
approved by the Company’s shareholders, Article 4 of the Company’s Articles of Incorporation would be amended and restated
in its entirety to read as follows:
“4. The
authorized capital stock of the Corporation shall be 500,000,000 shares of Common Stock, $0.01 par value.”
A copy of the proposed Amendment is attached
as Appendix A.
The additional authorized
shares of the Company’s Common Stock, if and when issued, would be part of the existing class of Common Stock and would have
the same rights and privileges as the shares of Common Stock presently issued and outstanding. Although the additional shares of
Common Stock would not have any effect on the rights and privileges of the Company’s existing shareholders, the issuance
of additional shares of Common Stock, other than in connection with a stock split or stock dividend, would have the effect of diluting
the voting power of existing shareholders and decreasing earnings and the book value attributable to shares presently issued and
outstanding. If the Amendment is approved, in general, no further approval of the Company’s shareholders will be required
prior to the issuance of additional shares of Common Stock.
The availability of
additional authorized but unissued shares of Common Stock may have the effect of discouraging attempts to take over control of
the Company, as additional shares of Common Stock could be issued to dilute the stock ownership and voting power of, or increase
the cost to, a party seeking to obtain control of the Company.
If the Amendment is
approved, it will become effective upon its filing with the Pennsylvania Secretary of the Commonwealth, which will occur as soon
as reasonably practicable after approval.
Required Vote
The affirmative vote
of a majority of the shares of Common Stock present in person or represented by proxy and voting at the Annual Meeting will be
required to approve this proposal.
THE BOARD
OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE FOR THE ADOPTION OF THIS PROPOSAL
PROPOSAL
ii
non-binding,
advisory vote on executive compensation
As required by Regulation 14A of the Exchange Act, we are seeking
shareholder approval, on an advisory basis, of the compensation of our named executive officers as disclosed under the “Executive
Compensation” section of this proxy statement. Accordingly, for the reasons discussed in the “Compensation Discussion
and Analysis” section of this proxy statement, we are asking our shareholders to vote “FOR” this proposal.
While we intend to carefully consider the voting results of
this proposal, the vote is advisory in nature and therefore not binding on us, our Board of Directors or our Compensation Committee.
Our Board of Directors and Compensation Committee value the opinions of all our shareholders and will consider the outcome of this
vote when making future compensation decisions for our named executive officers.
Approval of this proposal requires the favorable vote of a majority
of the votes cast by our shareholders.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE
FOR
THIS PROPOSAL TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED UNDER
THE “EXECUTIVE COMPENSATION” SECTION OF THIS PROXY STATEMENT.
PROPOSAL
iII
NON-BINDING ADVISORY VOTE ON FREQUENCY OF THE SHAREHOLDER
VOTE ON EXECUTIVE COMPENSATION
As required by Regulation 14A of the Exchange
Act, we are seeking a shareholder vote, on an advisory basis, on the frequency with which we include in our proxy statement an
advisory vote on executive compensation. By voting on this proposal, shareholders may indicate whether they prefer that we seek
such an advisory vote every one, two or three years. Pursuant to Section 14A of the Exchange Act, we are required to hold
at least once every six years an advisory shareholder vote to determine the frequency of the advisory shareholder vote on executive
compensation.
After consideration of this proposal, our Board of Directors
determined that an advisory vote on executive compensation that occurs every three years is the most appropriate alternative for
the Company and therefore recommends a vote for a triennial advisory vote. In reaching its recommendation, our Board of Directors
considered that a triennial advisory vote would permit the pay for performance elements of our compensation programs to be judged
over a period of time. Our Board of Directors believes that a well-structured compensation program should include policies and
practices that emphasize the creation of shareholder value over the long-term and that the effectiveness of such plans cannot be
best evaluated on an annual or biennial basis.
While we intend to carefully consider the voting results of
this proposal, the vote is advisory in nature and therefore not binding on us, our Directors or our Compensation Committee. Our
Board of Directors and Compensation Committee value the opinions of our all our shareholders and will consider the outcome of this
vote when deciding upon the frequency of shareholder votes on executive compensation.
Approval of this proposal requires the favorable vote of a majority
of the votes cast by our shareholders.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT AN ADVISORY
VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS BE HELD “
EVERY THREE YEARS
.”
SHAREHOLDER
PROPOSALS FOR NEXT YEAR
Shareholders who intend
to have a proposal considered for inclusion in the Company’s proxy materials for presentation at the 2014 Annual Meeting
of Shareholders pursuant to Rule 14a-8 under the Exchange Act must submit their proposal to us at the Company’s offices at
8250 Exchange Dr. Suite 120, Orlando, FL 32835, not later than December 22, 2013. The Company reserves the right to reject, rule
out of order, or take other appropriate action with respect to any proposal that does not comply with Rule 14a-8 and all other
applicable requirements.
HOUSEHOLDING
OF ANNUAL MEETING MATERIALS
Some banks, brokers
and other nominee record holders may be participating in the practice of “householding” proxy statements and annual
reports. This means that only one copy of the Company’s Proxy Statement or Annual Report may have been sent to multiple shareholders
in your household. The Company will promptly deliver a separate copy of either document to you if you write to the Company at 8250
Exchange Dr. Suite 120 Orlando, FL 32835, attention: Chairman or call the Company at (800) 558-4363. If you want to receive separate
copies of the Annual Report and Proxy Statement in the future, or if you are receiving multiple copies and would like to receive
only one copy for your household, you should contact your bank, broker, or other nominee record holder, or you may contact the
Company at the above address and phone number.
ANNUAL REPORT
ON FORM 10-K
The Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2012, including financial statements for such period, is being
mailed to shareholders with this Proxy Statement, but such report does not constitute a part of this Proxy Statement.
OTHER
MATTERS
As of the date hereof,
management does not intend to present, nor has it been informed that other persons intend to present, any matters for action at
the Meeting, other than those specifically referred to herein. If, however, any other matters should properly come before the Meeting,
it is the intention of the persons named in the proxies to vote the shares represented thereby in accordance with their best judgment
on such matters.
The expenses of soliciting
proxies in the form included with this Proxy Statement and the cost of preparing, assembling and mailing materials in connection
with such solicitation of proxies will be borne by the Company. In addition to the use of mail, the Company’s directors,
executive officers and employees may solicit proxies personally or by telephone.
|
|
By Order of the Board of Directors:
|
|
|
|
|
|
.
|
|
|
|
|
|
Bernard L. Kasten, Jr., M.D.
|
|
|
Chairman of the Board
|
April XX, 2013
APPENDIX A
ARTICLES OF AMENDMENT TO THE
ARTICLES OF INCORPORATION
OF
GENELINK, INC.
THE UNDERSIGNED BUSINESS
CORPORATION, desiring to amend its Articles of Incorporation, in compliance with the requirements of Section 1915 of the Pennsylvania
Business Corporation Law of 1988, hereby certifies that:
|
|
1.
|
The name of the Corporation is:
|
GeneLink, Inc.
|
|
2.
|
The address, including street and number, of the Corporation’s registered office is:
|
c/o CT Corporation
1635 Market Street
Philadelphia, PA 19103
(Philadelphia County)
|
|
3.
|
The statute under which the Corporation was incorporated is the Pennsylvania Business Corporation Law of 1988.
|
|
|
4.
|
The date of its incorporation is: January 6, 1995
|
|
|
5.
|
The amendment was adopted pursuant to Section 1914(a) of the Pennsylvania Business Corporation Law of 1988 by the Corporation’s
Shareholders.
|
|
|
6.
|
The amendment adopted by the Corporation, set forth in full, is as follows:
|
Article 4 of the Corporation’s
Articles of Incorporation is hereby amended to read in full as follows:
4. The
authorized capital stock of the Corporation shall be 500,000,000 shares of Common Stock, $0.01 par value.
IN WITNESS WHEREOF, the undersigned Corporation
has caused these Articles of Amendment to be signed by its duly authorized officer this ____ day of May, 2013.
|
|
|
GENELINK, INC.
|
|
|
|
|
|
|
By:
|
|
|
|
|
Bernard L. Kasten, Jr., M.D., Chief Executive Officer
|
RESOLUTIONS AUTHORIZED MARCH 22, 2013
BY BOARD OF DIRECTORS OF GENELINK, INC.
The undersigned, being the entire Board
of Directors of GeneLink, Inc., a Pennsylvania corporation (the “Company”), do hereby consent to the adoption of the
following Resolution to the same extent as though such action had been authorized at a meeting of the Board of Directors of the
Company held pursuant to notice:
RESOLVED, that the 2013 Annual Meeting of
Shareholders of the Company shall be held on May 30, 2013 at 9:00 a.m. at the GeneLink Corporate Offices at 8250 Exchange Dr. Suite
120, Orlando, FL 32835
FURTHER RESOLVED, that the record date for
the 2013 Annual Meeting of Shareholders shall be April 1, 2013.
FURTHER RESOLVED, that the preparation,
filing and delivery of the materials for the 2013 Annual Meeting of Shareholders, drafts of which will be presented to each director
prior to filing, be hereby authorized and approved.
FURTHER RESOLVED, that the proposed amendment
to the Company’s Articles of Incorporation, as more fully described in the proxy statement, increasing the authorized capitalization
from 350,000,000 shares of common stock to 500,000,000 shares of common stock be and it hereby is authorized and approved, subject
to shareholder approval at the 2013 Annual Meeting of Shareholders. Upon such approval the proper officers of this Company shall,
and they hereby are authorized, directed and empowered to, file a certificate of amendment with the Secretary of State of the Commonwealth
of Pennsylvania with respect to such amendment.
GeneLink (CE) (USOTC:GNLKQ)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
GeneLink (CE) (USOTC:GNLKQ)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
